688506 百利天恒
已收盘 01-21 15:00:00
资讯
新帖
简况
百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理
北京商报 · 01-20 20:14
百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理
贵州茅台等191股获推荐，百利天恒目标价涨幅超300%丨券商评级观察
南方财经网 · 01-19 09:53
贵州茅台等191股获推荐，百利天恒目标价涨幅超300%丨券商评级观察
每周股票复盘：百利天恒（688506）股东OAP拟减持不超1%股份
证券之星 · 01-18
每周股票复盘：百利天恒（688506）股东OAP拟减持不超1%股份
百利天恒股东OAP III(HK)Limited拟减持不超1%公司股份
财中社 · 01-16
百利天恒股东OAP III(HK)Limited拟减持不超1%公司股份
每周股票复盘：百利天恒（688506）EGFR×HER3双抗ADC纳入优先审评
证券之星 · 01-11
每周股票复盘：百利天恒（688506）EGFR×HER3双抗ADC纳入优先审评
百利天恒：首次回购14858股
南方财经网 · 01-08
百利天恒：首次回购14858股
百利天恒：关于取得金融机构股票回购专项贷款承诺函的公告
证券日报 · 01-07
百利天恒：关于取得金融机构股票回购专项贷款承诺函的公告
百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序
智通财经 · 01-06
百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序
百利天恒（688506）2.98亿股限售股将于1月6日解禁，占总股本72.2%
证券之星 · 01-06
百利天恒（688506）2.98亿股限售股将于1月6日解禁，占总股本72.2%
【读财报】A股1月逾2800亿元解禁 百利天恒、海博思创解禁规模居前
新华财经 · 01-05
【读财报】A股1月逾2800亿元解禁 百利天恒、海博思创解禁规模居前
每周股票复盘：百利天恒（688506）拟回购股份金额不低于1亿元
证券之星 · 01-02
每周股票复盘：百利天恒（688506）拟回购股份金额不低于1亿元
百利天恒：拟1亿元~2亿元回购股份 回购价格不超过546元/股
每日经济新闻 · 2025-12-30
百利天恒：拟1亿元~2亿元回购股份 回购价格不超过546元/股
百利天恒拟发行不超过100亿元债务融资工具
美股速递 · 2025-12-28
百利天恒拟发行不超过100亿元债务融资工具
百利天恒最新公告：拟申请注册发行不超过100亿元债务融资工具
证券之星 · 2025-12-28
百利天恒最新公告：拟申请注册发行不超过100亿元债务融资工具
每周股票复盘：百利天恒（688506）控股股东限售股将解禁并承诺不减持
证券之星 · 2025-12-28
每周股票复盘：百利天恒（688506）控股股东限售股将解禁并承诺不减持
百利天恒（688506）披露首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告，12月25日股价下跌3.22%
证券之星 · 2025-12-25
百利天恒（688506）披露首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告，12月25日股价下跌3.22%
百利天恒宣布2.981亿股限售股即将解禁，1月6日起上市流通
美股速递 · 2025-12-25
百利天恒宣布2.981亿股限售股即将解禁，1月6日起上市流通
12月18日百利天恒现292.42万元大宗交易
证券之星 · 2025-12-18
12月18日百利天恒现292.42万元大宗交易
四川新首富豪赌创新药：叫停港股IPO，百利天恒的“输血”与“造血”困局
华夏时报 · 2025-12-10
四川新首富豪赌创新药：叫停港股IPO，百利天恒的“输血”与“造血”困局
百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参
每日经济新闻 · 2025-12-01
百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":303,"timestamp":1768978800000,"preClose":304,"halted":0,"volume":1276841,"delay":0,"changeRate":-0.0033,"floatShares":401000000,"shares":413000000,"eps":-2.0646,"marketStatus":"已收盘","change":-1,"latestTime":"01-21 15:00:00","open":305,"high":309.56,"low":300.51,"amount":389000000,"amplitude":0.0298,"askPrice":303,"askSize":93,"bidPrice":302.93,"bidSize":6,"shortable":0,"etf":0,"ttmEps":-2.0646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769045400000},"marketStatusCode":5,"adr":0,"adjPreClose":304,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768959000000,1768966200000],[1768971600000,1768978800000]],"highLimit":334.4,"lowLimit":273.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":17.45,"roa":"--","roe":"--","epsLYR":9.25,"committee":-0.554286,"marketValue":125101000000,"turnoverRate":0.0032,"status":1,"afterMarket":{"amount":0,"volume":0,"close":303,"buyVolume":200,"sellVolume":0,"time":1768980663558,"indexStatus":"已收盘 01-21 15:30:00","preClose":304},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1768980665354,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":121503000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2604185671","title":"百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604185671","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604185671?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:14","pubTimestamp":1768911252,"startTime":"0","endTime":"0","summary":"百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203624898124.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624898124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","BK0239","688506"],"gpt_icon":0},{"id":"2604906375","title":"贵州茅台等191股获推荐，百利天恒目标价涨幅超300%丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2604906375","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604906375?lang=zh_cn&edition=full","pubTime":"2026-01-19 09:53","pubTimestamp":1768787617,"startTime":"0","endTime":"0","summary":"21财经1月19日电，南财投研通数据显示，1月12日至1月18日，券商给予上市公司目标价共92次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、湖南裕能、华立科技，目标价涨幅分别为319.47%、85.81%、58.27%，分别属于化学制药、电池、文娱用品行业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601193623000868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03189","91194","02615","600519","688506","83189"],"gpt_icon":0},{"id":"2604749925","title":"每周股票复盘：百利天恒（688506）股东OAP拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2604749925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604749925?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:38","pubTimestamp":1768682289,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，百利天恒报收于315.16元，较上周的343.9元下跌8.36%。公司公告汇总四川百利天恒药业股份有限公司关于持股5%以上股东减持股份计划公告截至公告披露日，OAP III Limited持有公司6.91%股份，计划自公告披露之日起十五个交易日后三个月内，通过集中竞价方式减持不超过公司总股本1.00%的股份，即不超过4,128,738股，减持原因为自身资金需求。本次减持计划符合相关法律法规及承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","91194","BK0239"],"gpt_icon":0},{"id":"2603492998","title":"百利天恒股东OAP III(HK)Limited拟减持不超1%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603492998","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603492998?lang=zh_cn&edition=full","pubTime":"2026-01-16 19:54","pubTimestamp":1768564470,"startTime":"0","endTime":"0","summary":"1月16日，百利天恒（688506）发布公告，股东OAPIII(HK)Limited因自身资金需求，计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持不超过413万股公司股份，占公司总股本的1%。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622097950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4134","688506","BK0239","91194","02615","III"],"gpt_icon":0},{"id":"2602536916","title":"每周股票复盘：百利天恒（688506）EGFR×HER3双抗ADC纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536916","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536916?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:57","pubTimestamp":1768075027,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，百利天恒报收于343.9元，较上周的323.1元上涨6.44%。本周关注点公司公告汇总：iza-bren用于治疗食管鳞癌被纳入优先审评程序。公司公告汇总四川百利天恒药业股份有限公司自主研发的注射用iza-bren被国家药品监督管理局药品审评中心纳入优先审评品种名单，适用于既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","688506","BK0239"],"gpt_icon":0},{"id":"2601363384","title":"百利天恒：首次回购14858股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363384","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601363384?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:48","pubTimestamp":1767869297,"startTime":"0","endTime":"0","summary":"南财智讯1月8日电，百利天恒公告，2026年1月8日公司通过集中竞价交易方式首次回购公司股份14,858股，占公司总股本的比例为0.0036%，回购成交的最高价为341.05元/股，最低价为332.81元/股，支付的资金总额为499.97万元（不含印花税、交易佣金等交易费用）。本次回购股份符合法律法规的规定及公司回购股份方案的要求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601083612915036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","BK0239","688506","91194"],"gpt_icon":0},{"id":"2601872229","title":"百利天恒：关于取得金融机构股票回购专项贷款承诺函的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2601872229","media":"证券日报","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601872229?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:11","pubTimestamp":1767784284,"startTime":"0","endTime":"0","summary":"证券日报网讯1月7日，百利天恒发布公告称，近日，公司取得中国银行股份有限公司四川省分行出具的《贷款承诺函》，主要内容如下：1、贷款承诺额度：不超过1.8亿元人民币。2、贷款期限：3年。3、贷款用途：专项用于回购公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611616331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","688506","91194","FISI","BK4211","BK0239"],"gpt_icon":0},{"id":"2601186053","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186053","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186053?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:53","pubTimestamp":1767689624,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，近日，公司自主研发的全球首创(First-in-class)、新概念(New concept)且唯一进入III期临床阶段的EGFR×HER3双抗ADC(注射用iza-bren)被国家药品监督管理局药品审评中心(简称“CDE”)纳入优先审评品种名单。根据公开资料查询，iza-bren也是全球首个被纳入优先审评品种名单的EGFR×HER3双抗ADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","688506","BK4231","91194","BK4080","02615","BK0239"],"gpt_icon":0},{"id":"2601855752","title":"百利天恒（688506）2.98亿股限售股将于1月6日解禁，占总股本72.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601855752","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601855752?lang=zh_cn&edition=full","pubTime":"2026-01-06 08:11","pubTimestamp":1767658269,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，百利天恒于1月6日将有2.98亿股限售股份解禁，为公司首发原股东限售股份，占公司总股本72.2%。最近一年内，该股累计解禁1244.01万股，占总股本的3.01%。本次解禁后，公司还有1187.38万股限售股份，占总股本2.88%。百利天恒主营业务：药品的研发、生产与营销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600006230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2601020887","title":"【读财报】A股1月逾2800亿元解禁 百利天恒、海博思创解禁规模居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2601020887","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601020887?lang=zh_cn&edition=full","pubTime":"2026-01-05 07:12","pubTimestamp":1767568375,"startTime":"0","endTime":"0","summary":"新华财经北京1月5日电2026年1月，A股有117家公司的限售股面临解禁，合计解禁量约为102.02亿股，解禁规模2895.87亿元，环比下降约14.13%，同比上升约12.57%。其中，百利天恒解禁规模居首，解禁市值超900亿元。从行业分布来看，医药生物、电力设备、汽车行业解禁市值分别位列前三。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608072267.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399300","688411","91194","159982","02615","688506"],"gpt_icon":0},{"id":"2600036847","title":"每周股票复盘：百利天恒（688506）拟回购股份金额不低于1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036847?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:36","pubTimestamp":1767292571,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，百利天恒报收于338.55元，较上周的354.62元下跌4.53%。本周，百利天恒12月22日盘中最高价报355.48元。本周关注点公司公告汇总：百利天恒拟以集中竞价方式回购股份，金额不低于1亿元且不超过2亿元。公司公告汇总：公司拟申请注册发行债务融资工具，规模不超过人民币100亿元。本次发行需经公司股东会审议及中国银行间市场交易商协会注册批准，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","02615","91194"],"gpt_icon":0},{"id":"2595799938","title":"百利天恒：拟1亿元~2亿元回购股份 回购价格不超过546元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595799938","media":"每日经济新闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595799938?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:50","pubTimestamp":1767091842,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月30日，百利天恒(688506.SH)公告称，公司拟以集中竞价交易方式回购公司股份，回购金额不低于1亿元且不超过2亿元，回购价格不超过546元/股。回购的股份将在未来适宜时机全部用于实施员工持股计划或股权激励。若公司未能在股份回购实施结果暨股份变动公告日后3年内使用完毕已回购股份，尚未使用的已回购股份将予以注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605828117.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605828117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","688506","BK0239"],"gpt_icon":0},{"id":"1136738692","title":"百利天恒拟发行不超过100亿元债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=1136738692","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136738692?lang=zh_cn&edition=full","pubTime":"2025-12-28 15:50","pubTimestamp":1766908212,"startTime":"0","endTime":"0","summary":"百利天恒公告称，公司计划发行总额不超过100亿元人民币的债务融资工具。此次融资将用于优化债务结构及补充营运资金，具体发行条款将根据市场情况和公司需求确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2594221865","title":"百利天恒最新公告：拟申请注册发行不超过100亿元债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2594221865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594221865?lang=zh_cn&edition=full","pubTime":"2025-12-28 15:50","pubTimestamp":1766908207,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司拟在中国银行间交易市场申请注册发行债务融资工具，发行规模不超过100亿元，品种包括中期票据、短期融资券等。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800002883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2594077241","title":"每周股票复盘：百利天恒（688506）控股股东限售股将解禁并承诺不减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2594077241","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594077241?lang=zh_cn&edition=full","pubTime":"2025-12-28 02:17","pubTimestamp":1766859432,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，百利天恒报收于338.55元，较上周的354.62元下跌4.53%。本周，百利天恒12月22日盘中最高价报355.48元。公司公告汇总：控股股东朱义自愿承诺限售期满后12个月内不以任何方式减持公司股份。公司公告汇总四川百利天恒药业股份有限公司首次公开发行部分限售股将于2026年1月6日上市流通，本次解除限售股份数量为298,108,880股，占公司当前总股本的72.2034%，限售期为36个月。保荐人中信证券对本次限售股上市流通事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","688506","BK0239"],"gpt_icon":0},{"id":"2594378092","title":"百利天恒（688506）披露首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告，12月25日股价下跌3.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594378092","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594378092?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:07","pubTimestamp":1766671628,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，百利天恒报收于331.0元，较前一交易日下跌3.22%，最新总市值为1366.61亿元。近日，四川百利天恒药业股份有限公司发布关于首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告。公告显示，公司首次公开发行部分限售股将于2026年1月6日上市流通，本次解除限售股份数量为298,108,880股，占公司当前总股本的72.2034%，限售期为36个月。本次解除限售股东为公司控股股东、实际控制人朱义先生。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500035809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","02615","688506"],"gpt_icon":0},{"id":"1177744413","title":"百利天恒宣布2.981亿股限售股即将解禁，1月6日起上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=1177744413","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177744413?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:44","pubTimestamp":1766655876,"startTime":"0","endTime":"0","summary":"百利天恒公告称，公司约2.981亿股限售股份的锁定期即将届满，这部分股份将于1月6日起正式上市流通交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2592974802","title":"12月18日百利天恒现292.42万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974802","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592974802?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:51","pubTimestamp":1766051502,"startTime":"0","endTime":"0","summary":"证券之星消息，12月18日百利天恒发生大宗交易，交易数据如下：大宗交易成交价格348.12元，成交0.84万股，成交金额292.42万元，买方营业部为华泰证券股份有限公司马鞍山湖东中路证券营业部，卖方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部。近三个月该股共发生3笔大宗交易，合计成交1037.0手。截至2025年12月18日收盘，百利天恒报收于348.12元，下跌0.98%，换手率0.56%，成交量5768.0手，成交额2.03亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800027318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239","02615"],"gpt_icon":0},{"id":"2590448581","title":"四川新首富豪赌创新药：叫停港股IPO，百利天恒的“输血”与“造血”困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590448581","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590448581?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:50","pubTimestamp":1765367400,"startTime":"0","endTime":"0","summary":"华夏时报记者 王瑜 于娜 北京报道随着百利天恒(688506.SH）市值从百亿元跃升为千亿元，公司创始人、董事长朱义一举问鼎四川首富。这位自称“打麻将都要All in”的狠人，在创新药赛道上更是 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20251210/c673110112.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251210/c673110112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688506","159992","BK0239"],"gpt_icon":0},{"id":"2588371664","title":"百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588371664","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588371664?lang=zh_cn&edition=full","pubTime":"2025-12-01 07:13","pubTimestamp":1764544408,"startTime":"0","endTime":"0","summary":"｜2025年12月1日星期一｜NO.1百利天恒收到百时美施贵宝里程碑付款百利天恒公告，子公司SystImmune已收到由百时美施贵宝支付的2.5亿美元里程碑付款。据合作协议，公司后续还有资格获得最高可达2.5亿美元的近期或有付款，以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件，最终里程碑付款尚存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512013578546745.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512013578546745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK1161","BK1515","BK1574","688062","02615","BK0239","159938","09939","688506"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768980665859,"stockEarnings":[{"period":"1week","weight":-0.116},{"period":"1month","weight":-0.1427},{"period":"3month","weight":-0.1437},{"period":"6month","weight":-0.0222},{"period":"1year","weight":0.5544},{"period":"ytd","weight":-0.0591}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0574},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1409},{"period":"1year","weight":0.2679},{"period":"ytd","weight":0.0365}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5979人(较上一季度增加25.08%)","perCapita":"67068股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}